Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms

Pharmacy World and Science

Volumn 27, Issue 6, 2005, Pages 459-464

  Grau, Santiago ^a   Antonio, Javier Mateu De ^a   Soto, Javier ^b   Marín Casino, Mónica ^a   Salas, Esther ^a  

^a HOSPITAL DEL MAR   (Spain)

^b PFIZER INC   (United States)

Author keywords

Cost effectiveness analysis; Gram positive bacteremia; Linezolid; Pharmacoeconomics; Teicoplanin

Indexed keywords

ANTIBIOTIC AGENT; LINEZOLID; TEICOPLANIN;

ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; GRAM POSITIVE BACTERIUM; HUMAN; NONHUMAN;

ACETAMIDES; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITAL COSTS; HUMANS; MODELS, ECONOMIC; OXAZOLIDINONES; TEICOPLANIN;

EID: 28944442416     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-005-1638-8     Document Type: Article

References (31)

1. J Oteo S Cruchaga J Campos JA Sáez F Baquero Spanish members of the European Group of Antimicrobial Resistance Surveillance System (EARSS) 2002 Resistencia a antibióticos en Staphylococcus aureus aislados de sangre de 31 hospitales españoles de la Red Europea de Vigilancia de Resistencia a Antibióticos (2000) Med Clin (Barc) 119 361 5
2. A Asensio R Cantón J Vaqué J Rosselló JL Arribas EPINE group 2002 Etiología de las infecciones hospitalarias en España (EPINE, 1990-1999) Med Clin (Barc) 118 725 30
3. Cantón R, Asensio A.. Prevalencia del uso de antimicrobianos. In Vaqué J, Roselló J, editors. Evolución de la prevalencia de las infecciones nosocomiales en hospitales españoles. EPINE 1990-1999; 299-336
4. EARSS Management Team 2000 European antimicrobial resistance surveillance system EARSS Newsletter 3 1 8
5. R Cantón N Mir M Martínez-Ferrer B Sánchez del Sanz I Soler F Baquero 1999 Estudio prospectivo de Staphylococcus aureus con sensibilidad disminuída a los glucopéptidos Rev Esp Quimioter 12 48 53
6. M Aymerich A García Altes AJ Jovell 1999 Las resistencias bacterianas: ¿algo más que un problema clínico? La resistencia del enterococo a la vancomicina como ejemplo Med Clin (Barc) 112 553 5
7. JJ Schentag 2001 Antimicrobial management strategies for bacterial Gram-positive resistance in the intensive care unit Crit Care Med 29 Suppl 100 7
8. D Clemett A Markham 2000 Linezolid Drugs 59 815 28
9. KT Bain EI Wiftbrodt 2001 Linezolid for the treatment of resistant Gram-positive cocci Ann Pharmacother 35 566 75
10. DJ Diekema RN Jones 2001 Oxazolidinone antibiotics Lancet 358 1975 82
11. CM Perry B Jarvis 2001 Linezolid. A review of its uses in the management of serious Gram-positive infections Drugs 61 525 51
12. Z Li RJ Willke LA Pinto 2001 Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin. A randomised, multicenter trial Pharmacotherapy 21 263 74
13. Wilcox M, Tang L, Hafkin B.. Linezolid versus teicoplanin for the treatment of hospitalized patients with Gram positive infections poster 1481. 41st interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, December 2001
14. RJ Willke HAS Glick JZ Li BE Rittenhouse 2002 Effects of linezolid on hospital length of stay compared with vancomycin in treatments of methicillin-resistant Staphylococcus infections Int J Tec Assess Health Care 18 540 54
15. J Li D Balan R Willke 2002 Comparison of hospital resource uses between linezolid and teicoplanin for the treatment of bacterial Gram-positive infections: results of a multicentre trial. Abstract Clin Microbiol infec 8 Supp 1 83
16. M Wilcox D Nathwani M Dryden 2004 Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections J Antimicrob Chemother 53 335 44
17. H Lopez JZ Li DA Balan 2003 Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious Gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial Clin Ther 25 1846 71
18. D Nathwani JZ Li DA Balan RJ Willke BE Rittenhouse E Mozaffari 2004 An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects Int J Antimicrob Agents 23 315 24
19. G Delgado MM Neuhauser DI Bearden LH Dazinger 2000 Quinupristin- dalfopristin: an overview Pharmacotherapy 20 1469 85
20. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. NDA-I1: NDA approval letter, 2003. Available at http://www.fda. gov/cder/foi/appletter/2003/21572ltr. pdf. Accessed February 2, 2004
21. RG Wunderink SK Cammarata TH Oliphant MH Kollef 2003 Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia Clin Ther 25 980 92
22. RG Wunderink J Rello SK Cammarata RV Croos-Dabrera MH Kollef 2003 Linezolid versus vancomycin. Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia Chest 124 1789 97
23. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intens Care Med 2004; 30: 388-94; published online 9 January 2004. DOI: 10.1007/s00134-003-2088-1
24. JZ Li RJ Willke BE Rittenhouse HAS Glick 2002 Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomised clinical trial: for linezolid versus vancomycin treatment of known or suspected methicillin-resistant Staphylococcus species infections Pharmacotherapy 22 2 pt 2 45s 54s
25. To Vinken Z Li D Bleat B Rittenhouse R Willke D Nathwani 2001 Economic evaluation of linezolid, flucoxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model J Hosp Infect 49 Suppl A s13 24
26. AF Shorr GM Susla MH Kollef 2004 Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Crit Care Med 32 137 43
27. JA Cepeda T Whitehouse B Cooper 2004 Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study J Antimicrob Chemother 53 345 55
28. APR Wilson RN Grüneberg H Neu 1994 A critical review of the dosage of teicoplanin in Europe and the USA Int J Antimicrob Agents 4 Suppl. 1 s1 30
29. MF Drummond WS Richardson BJ O'Brien M Levine D Heyland 1997 Users guides to medical the literature. XIII How to uses an article on economic clinical analysis of practice J Am Med Assoc 277 1552 7
30. R Del Campo C Tenorio M Zarazaga R Gómez-Lus F Baquero C Torres 2001 Detection of to single vanA-containing Enterococcus faecalis done in hospitals in different regions in Spain J Antimicrob Chemother 48 735 48
31. BH Normark R Novak A Örtquist G Källenius E Tuomanen S Normark 2001 Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin Clin Infect Dis 32 552 8